This trial is evaluating whether EPOCH will improve 1 primary outcome and 1 secondary outcome in patients with Burkitt Lymphoma. Measurement will happen over the course of Time of progression.
This trial requires 348 total participants across 1 different treatment group
This trial involves a single treatment. EPOCH is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Lymphoma, diffuse can lead to high levels f plasma proteins, low platelets, low white blood cell levels, low neutrophils levels and anemia. T cell lymphoma presents more with fever, night sweats and night sweats. Tumor sites (lymphadenopathy, bone marrow, intestine, tonsils, eye) are the most common in the United States. Unexplained weight loss, swelling or painful spots occur with Hodgkin lymphoma. Symptoms of acute leukemia depend on disease type. Symptoms are often preceded by nonspecific fevers, chills, tiredness and low white blood cell levels. The most common symptom of acute lymphocytic leukemia is loss of appetite and fatigue." - Anonymous Online Contributor
"A recent survey of lymphoma in 3 US counties using the SEER database revealed a rate of 25 cases per 100,000 per year. This rate is approximately five times greater than the average value for all lymphomas in the US, a more than 400 times greater rate than the average rate for all B-cell lymphomas, and even twice as high as the rate of non-Hodgkin's lymphomas in lymphoma-bearing populations. The fact that such a high rate of disease can persist despite significant improvements in chemotherapy and radiotherapy underscores the need to consider lymphoma as a major public health problem." - Anonymous Online Contributor
"The presentation of DLBCL, diffuse is characterized by a nonspecific clinical course; the disease responds well to chemotherapy but often relapses, typically after 5-7 years, with excellent overall survival rates of 80-90% under current treatment." - Anonymous Online Contributor
"It's important to take in consideration that due to the different pathological mechanism of NHL cell, their treatments also varies. The majority of the cases are with combination of chemotherapy or monochemotherapy, combined with radiotherapy. Bortezomib and rituximab are used for advanced aggressive NHL. With combination chemotherapy of gemtuzumab ozogamicin, anthracycline and a taxane, an anthracycline backbone treatment can be offered." - Anonymous Online Contributor
"The exact cause of diffuse lymphoma remains a mystery. Nevertheless, the likelihood of having an underlying connective tissue disorder, such as Sjögren's syndrome or dermatomyositis, as well as genetic predisposition, may be considered when treating patients with this type of lymphoma." - Anonymous Online Contributor
"Even after aggressive therapy, some patients with LDLD and DLNB can have persistent disease for long periods of time, usually accompanied by progressive and irreversible complications of these diseases." - Anonymous Online Contributor
"This review shows that the primary cause of lymphoma in children may be infection rather than malignant neoplastic changes in B cells. This suggests a potential role for rituximab treatment in lymphoma with an undefined primary." - Anonymous Online Contributor
"Lymphoma, diffuse was not associated with a higher chance of developing chronic, long-term lymphoma. These people had an increased risk of developing solid tumors. Lymphoma, diffuse was not associated with an increased risk of developing a lymphoma that was more aggressive. These patients also had higher rates of B-cell lymphoma. Findings from a recent study deserve further evaluation in the future to determine if further studies are warranted." - Anonymous Online Contributor
"The International Working Group of the European Hodgkin Disease Group stated that the original definition of remission was met by the best of all published criteria, that is, an objective complete radiographic resolution of the disease process, no residual evidence of disease and complete normalization of the tumor markers of tumor cell activity. The definition is used by modern clinical investigators to determine the adequacy of Hodgkin disease clinical trials. In this article we recommend the definition of an objective complete resolution of the disease process, no residual evidence of disease, and normality of the tumor markers of tumor cell activity. The objective criteria of the working group can be used in place of the outdated criteria by any investigator when assessing the adequacy of clinical trials." - Anonymous Online Contributor
"The advances in immunotherapy are promising in both advanced B-cell lymphomas as well as solid tumors and it is anticipated that these approaches will become more important in the treatment and management of indolent lymphomas. It is anticipated that the targeted inhibition of the programmed death-1 (PD-1) pathway will be of increasing use in selected cases with solid tumors. Immunotherapy is also expected to be the next step in targeted therapy for systemic lupus erythematosus and scleroderma." - Anonymous Online Contributor
"Survival rates do vary according to the subgroups studied and the treatment strategy used. Survival rates of patients with diffuse large B-cell lymphoma remain poor given the current staging criteria of WHO, Ann Arbor Stage. There is an urgent need for better staging criteria." - Anonymous Online Contributor
"Both EP and placebo improved patient survival and tumor control. However, no clear difference was observed between the groups in terms of time to progression." - Anonymous Online Contributor